Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1

被引：0
|
作者：
Bota, Daniela A. [1 ]
Piccioni, David E. [2 ]
Duma, Christopher M. [3 ,4 ]
LaRoca, Renato V.
Kesari, Santosh [5 ,6 ,7 ]
Abedi, Mehrdad [8 ]
Aiken, Robert D. [9 ]
Poole, Aleksandra J. [10 ]
Nistor, Gabriel I. [10 ]
Dillman, Robert O. [10 ]
机构：
[1] Univ Calif Irvine, Irvine, CA USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
[3] Hoag Hosp, Newport Beach, CA USA
[4] Hoag Neurosci Inst, Newport Beach, CA USA
[5] Norton Canc Inst, Louisville, KY USA
[6] John Wayne Canc Inst, Santa Monica, CA USA
[7] Pacific Neurosci Inst, Santa Monica, CA USA
[8] Univ Calif Davis, Sacramento, CA 95817 USA
[9] Rutgers Canc Ctr, New Brunswick, NJ USA
[10] AIVITA Biomed Inc, Irvine, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT571
引用
收藏
页数：2
相关论文
共 9 条
  • [1] TUMOR MARKERS ASSOCIATED WITH INCREASED SURVIVAL IN A PHASE II TRIAL OF DENDRITIC CELL/TUMOR-INITIATING-CELL VACCINE AV-GBM-1 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Bota, Daniela
    Piccioni, David
    Duma, Christopher
    LaRocca, Renato
    Kesari, Santosh
    Carrillo, Jose
    Hsu, Frank
    Kong, Xiao-Tang
    Abedi, Mehrdad
    Aiken, Robert
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A357 - A357
  • [2] CHANGES IN PROTEOMIC MARKERS AFTER INJECTIONS OF PERSONAL AV-GBM-1 DENDRITIC CELL/TUMOR INITIATING CELL VACCINES IN A PHASE II TRIAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Kesari, Santosh
    Bota, Daniela
    Piccioni, David
    Duma, Christopher
    LaRocca, Renato
    Kong, Xiao-Tang
    Hsu, Frank
    Carrillo, Jose
    Abedi, Mehrdad
    Aiken, Robert
    Taylor, Thomas
    Poole, Aleksandra
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A359 - A359
  • [3] PHASE II TRIAL OF AV-GBM-1: DENDRITIC CELL VACCINE PULSED WITH LYSATE ENRICHED FOR AUTOLOGOUS TUMOR-INITIATING CELL ANTIGENS IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Bota, Daniela
    Piccioni, David
    Duma, Christopher
    LaRocca, Renato
    Kesari, Santosh
    Abedi, Mehrdad
    Carrillo, Jose
    Aiken, Robert
    Hsu, Frank
    Kong, Xiaotang
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1001 - A1001
  • [4] ADVERSE EVENTS IN A PHASE II TRIAL OF AV-GBM-1: DENDRITIC CELL VACCINE PULSED WITH LYSATE ENRICHED FOR AUTOLOGOUS TUMOR-INITIATING CELL ANTIGENS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Piccioni, David
    Piccioni, David
    Bota, Daniela
    LaRocca, Renato
    Kesari, Santosh
    Carillo, Jose
    Kong, Xiao-Tang
    Duma, Christopher
    Abedi, Mehrdad
    Aiken, Robert
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A362 - A362
  • [5] Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
    Bota, Daniela A.
    Taylor, Thomas H.
    Piccioni, David E.
    Duma, Christopher M.
    LaRocca, Renato V.
    Kesari, Santosh
    Carrillo, Jose A.
    Abedi, Mehrdad
    Aiken, Robert D.
    Hsu, Frank P. K.
    Kong, Xiao-Tang
    Hsieh, Candace
    Bota, Peter G.
    Nistor, Gabriel I.
    Keirstead, Hans S.
    Dillman, Robert O.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [6] LEUKAPHERESES TO OBTAIN MONOCYTES TO PRODUCE DENDRITIC CELLS IN MANUFACTURING OF PERSONAL AUTOLOGOUS AV-GBM-1 VACCINES IN A PHASE II TRIAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    LaRocca, Renato
    Bota, Daniela
    Piccione, David
    Duma, Christopher
    Kesari, Santosh
    Carrillo, Jose
    Kong, Xiang-Tang
    Hsu, Frank
    Aiken, Robert
    Abedi, Mehrdad
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A361 - A361
  • [7] TUMOR COLLECTION AND ESTABLISHMENT OF TUMOR-INITIATING CELL CULTURES AS ANTIGEN SOURCE FOR AV-GBM-1 DENDRITIC CELL VACCINES FOR A PHASE II TRIAL IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Duma, Christopher
    Bota, Daniela
    Hsu, Frank
    Piccioni, David
    LaRocca, Renato
    Kesari, Santosh
    Abedi, Mehrdad
    Carrillo, Jose
    Aiken, Robert
    Kong, Xiao-Tang
    Taylor, Thomas
    Hsieh, Candace
    Nistor, Gabriel
    Dillman, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A358 - A358
  • [8] Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
    Daniela A. Bota
    Thomas H. Taylor
    David E. Piccioni
    Christopher M. Duma
    Renato V. LaRocca
    Santosh Kesari
    Jose A. Carrillo
    Mehrdad Abedi
    Robert D. Aiken
    Frank P. K. Hsu
    Xiao-Tang Kong
    Candace Hsieh
    Peter G. Bota
    Gabriel I. Nistor
    Hans S. Keirstead
    Robert O. Dillman
    Journal of Experimental & Clinical Cancer Research, 41
  • [9] PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL
    Bota, Daniela
    Piccioni, David
    LaRocca, R.
    Duma, Christopher
    Kesari, Santosh
    Carrillo, Jose
    O'Donnell, Robert T.
    Aiken, Robert
    Hsu, Frank
    Kong, Xiao-Tang
    Hsieh, Candace
    Langford, Chris
    Carta, Krystal
    Wang, Adrienne
    Langford, James
    Taylor, Thomas
    Nistor, Gabriel
    Dillman, Robert
    NEURO-ONCOLOGY, 2020, 22 : 38 - 39
1